Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aramchol in Subjects With Hepatic Impairment

NCT04480827 is registered in ClinicalTrials.gov with Galmed Research and Development, Ltd. as lead sponsor.

NCT NCT04480827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aramchol in Subjects With Hepatic Impairment
Lead sponsor
Galmed Research and Development, Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 13, 2020
Completion date
March 24, 2022
Enrollment
57 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment